DDW Highlights: 13 March 2023

<p><span data-contrast="none">Perhaps most interestingly this week, after previous caution over in vivo gene therapy trials, the FDA has given the go ahead to </span><span data-contrast= "auto">Intellia Therapeutics to study NTLA-2002 in hereditary angioedema (HAE).</span><span data-ccp-props= "{"134233117":false,"134233118":false,"134245418":false,"201341983":0,"335559738":0,"335559739":0,"335559740":240}"> </span></p> <p><span data-contrast="auto">There have been several other announcements related to clinical trials in the last few days, including positive data from trials in severe influenza and biliary tract cancer, the launch of a study into an ADC treatment for solid tumours, and a new research partnership with the mission to improve clinical trial design.</span><span data-ccp-props= "{"134233117":false,"134233118":false,"134245418":false,"201341983":0,"335559738":0,"335559739":0,"335559740":240}"> </span></p> <p><span data-contrast="auto">You can listen below, or find The Drug Discovery World Podcast on</span> <a href= "https://open.spotify.com/show/5HpeK1T3H1VQIB1fiwn0KQ"><span data-contrast="none">Spotify</span></a><span data-contrast="none">, </span><a href="https://play.google.com/store/apps/details?id=com.edify.ddw"><span data-contrast="none">Google Play</span></a> <span data-contrast= "auto">and </span><a href= "https://apps.apple.com/gb/app/drug-discovery-world-ddw/id1530786395"><span data-contrast="none">Apple Podcasts.</span></a><span data-ccp-props= "{"201341983":0,"335559739":160,"335559740":259}"> </span></p>